News

SLN124 is being developed for the treatment of iron overload disorders like ß -Thalassemia, Myelodysplastic syndrome (MDS) and Hereditary Hemochromatosis (HH). The investigational candidate was demonstrated to reduce

The multimillion-pound drug discovery alliance will bring together Cancer Research UK’s network of scientists and drug discovery expertise, LifeArc’s therapeutic antibody engineering and development expertise and Ono’s expertise

These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti‐microbial resistance (AMR). MedPharm is a world

Mayzent is claimed to the first oral drug to treat secondary progressive MS with active disease. Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS),

This approval marks the first country approval in the world for SKYRIZI. “With this first global approval of SKYRIZI, we are excited to bring a new treatment option

Under the terms of the extension agreement, Transgene will contribute its industry-leading OV design and engineering expertise, some non-antibody transgenes, as well as its proprietary engineered vaccinia virus

The open-label mid-stage trial of SFX-01, which was launched in January 2017, was carried out in 46 patients with estrogen-positive (ER+) metastatic breast cancer. SFX-01 is a synthetic

This is the first approval of Forxiga for the treatment of patients with T1D. Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals,

The companies have reached settlement more than five years after the litigation started with Xarelto. During the period, all six cases related to Xarelto went to trial. Bayer